Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal Stem Cells + Mesenchymal Stem Cell-derived Extracellular Vesicles (Royan Institute)
- Development stage
- Unknown
- Lead developer
- Royan Institute for Stem Cell Biology and Technology
- Modality
- Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Cell therapy protocol 2 is a combination therapeutic regimen developed by the Royan Institute for the treatment of Acute Respiratory Distress Syndrome (ARDS), specifically in patients with COVID-19. The protocol involves the sequential administration of allogeneic Mesenchymal Stem Cells (MSCs) and MSC-derived Extracellular Vesicles (EVs). MSCs are known for their potent immunomodulatory properties, secreting anti-inflammatory factors and interacting with host immune cells to mitigate the hyper-inflammatory response or 'cytokine storm' characteristic of severe ARDS. The subsequent administration of EVs—nano-sized membrane vesicles containing bioactive proteins, mRNA, and microRNA—aims to enhance lung tissue repair and stabilize the alveolar-capillary barrier. This dual approach is designed to provide both immediate cellular immunomodulation and sustained regenerative signaling to improve respiratory function and survival in critically ill patients.
- Other names
- MSC + EV therapyMSC-EV combination therapyCell therapy protocol 2-Royan Institute-acute respiratory distress syndrome
Beyond the preview
Go deeper on Mesenchymal Stem Cells + Mesenchymal Stem Cell-derived Extracellular Vesicles (Royan Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mesenchymal Stem Cells + Mesenchymal Stem Cell-derived Extracellular Vesicles (Royan Institute).